Yarrow Bioscience
YARW
17 hedge funds and large institutions have $1.63M invested in Yarrow Bioscience in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
47% more capital invested
Capital invested by funds: $1.1M → $1.63M (+$524K)
1.2% more ownership
Funds ownership: 11.01% → 12.22% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less funds holding
Funds holding: 21 → 17 (-4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$311K |
| 2 |
Renaissance Technologies
New York
|
+$55.9K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.5K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.39K |
| 5 |
Morgan Stanley
New York
|
+$4.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$84K |
| 2 |
HF
HRT Financial
New York
|
-$31K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.93K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$148 |
YARW Hedge Fund Activity: Q2 2023 in Review
17 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2023, worth a combined $1.63M — up 47% from $1.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of YARW and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, adding an estimated $311K. The largest seller was Millennium Management, exiting entirely with an estimated $84K sold.
- 17 institutional investors held Yarrow Bioscience (YARW) as of Q2 2023, down from 21 in Q1 2023.
- Funds reported $1.63M of Yarrow Bioscience stock for Q2 2023, up 47% quarter-over-quarter.
- 0 funds opened new Yarrow Bioscience positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest Yarrow Bioscience buyer in Q2 2023 was Susquehanna International Group, an estimated $311K added.
- The largest Yarrow Bioscience seller in Q2 2023 was Millennium Management, an estimated $84K sold.
Based on aggregated 13F filings for Q2 2023.